Corium International, a commercial-stage pharmaceutical company specializing in adhesive drug delivery, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $61 million by offering 5.5 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Corium would command a fully diluted market value of $201 million.
Corium International, which was founded in 1995 and booked $48 million in sales for the 12 months ended December 31, 2013, plans to list on the NASDAQ under the symbol CORI. Corium International initially filed confidentially on December 23, 2013. Jefferies and Leerink Partners are the joint bookrunners on the deal.
